Ketamine exerts antidepressant effects and reduces IL-1β and IL-6 levels in rat prefrontal cortex and hippocampus

Experimental and Therapeutic Medicine

Volumn 5, Issue 4, 2013, Pages 1093-1096

  Yang, Chun ^a   Hong, Tao ^a   Shen, Jiang ^a   Ding, Jie ^a   Dai, Xiong Wei ^a   Zhou, Zhi Qiang ^b   Yang, Jian Jun ^b  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Antidepressant effects; Hippocampus; Interleukin 1 ; Interleukin 6; Ketamine; Prefrontal cortex

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; KETAMINE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMOBILIZATION; MALE; NONHUMAN; PREFRONTAL CORTEX; PROTEIN EXPRESSION; RAT;

EID: 84874626729     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.930     Document Type: Article

References (26)

1. Kessler RC, Berglund P, Demler O, et al: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105, 2003.
2. Berton O and Nestler EJ: New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7: 137-151, 2006.
3. Uppal A, Singh A, Gahtori P, Ghosh SK and Ahmad MZ: Antidepressants: current strategies and future opportunities. Curr Pharm Des 16: 4243-4253, 2010.
4. Mitchell AJ: Two-week delay in onset of action of antidepressants: new evidence. Br J Psychiatry 188: 105-106, 2006.
5. Wright CE, Strike PC, Brydon L and Steptoe A: Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun 19: 345-350, 2005.
6. Dantzer R: Cytokine-induced sickness behavior: mechanisms and implications. Ann NY Acad Sci 933: 222-234, 2001.
7. Pollak Y and Yirmiya R: Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment. Int J Neuropsychopharmacol 5: 389-399, 2002.
8. Skolnick P, Popik P and Trullas R: Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30: 563-569, 2009.
9. Machado-Vieira R, Salvadore G, Diazgranados N and Zarate CA Jr: Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123: 143-150, 2009.
10. Dale O, Somogyi AA, Li Y, Sullivan T and Shavit Y: Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis. Anesth Analg 115: 934-943, 2012.
11. Ward JL, Harting MT, Cox CS Jr and Mercer DW: Effects of ketamine on endotoxin and traumatic brain injury induced cytokine production in the rat. J Trauma 70: 1471-1479, 2011.
12. Takahashi T, Kinoshita M, Shono S, et al: The effect of ketamine anesthesia on the immune function of mice with postoperative septicemia. Anesth Analg 111: 1051-1058, 2010.
13. Yang C, Hu YM, Zhou ZQ, Zhang GF and Yang JJ: Acute administration of ketamine in rats increases hippocampal BDNF and mTOR levels during forced swimming test. Ups J Med Sci: Sep 13, 2012 (Epub ahead of print).
14. Busch CJ, Spöhr FA, Motsch J, Gebhard MM, Martin EO and Weimann J: Effects of ketamine on hypoxic pulmonary vasocon-striction in the isolated perfused lungs of endotoxaemic mice. Eur J Anaesthesiol 27: 61-66, 2010.
15. Nakayama M and Murray PA. Ketamine preserves and propofol potentiates hypoxic pulmonary vasoconstriction compared with the conscious state in chronically instrumented dogs. Anesthesiology 91: 760-771, 1999.
16. Taniguchi T and Yamamoto K: Anti-inflammatory effects of intravenous anesthetics on endotoxemia. Mini Rev Med Chem 5: 241-245, 2005.
17. Sun J, Zhou ZQ, Lv R, Li WY and Xu JG: Ketamine inhibits LPS-induced calcium elevation and NF-kappa B activation in monocytes. Inflamm Res 53: 304-308, 2004.
18. Raedler TJ: Inflammatory mechanisms in major depressive disorder. Curr Opin Psychiatry 24: 519-525, 2011.
19. Hannestad J, DellaGioia N and Bloch M: The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 36: 2452-2459, 2011.
20. Catena-Dell'Osso M, Bellantuono C, Consoli G, Baroni S, Rotella F and Marazziti D: Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development? Curr Med Chem 18: 245-255, 2011.
21. Song C and Wang H: Cytokines mediated inflammation and decreased neurogenesis in animal models of depression. Prog Neuropsychopharmacol Biol Psychiatry 35: 760-768, 2011.
22. Owen BM, Eccleston D, Ferrier IN and Young AH: Raised levels of plasma interleukin-1beta in major and postviral depression. Acta Psychiatr Scand 103: 226-228, 2001.
23. Piletz JE, Halaris A, Iqbal O, et al: Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J Biol Psychiatry 10: 313-323, 2009.
24. Brambilla F, Monteleone P and Maj M: Interleukin-1beta and tumor necrosis factor-alpha in children with major depressive disorder or dysthymia. J Affect Disord 78: 273-277, 2004.
25. Castanon N, Bluthe RM and Dantzer R: Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology (Berl) 154: 50-60, 2001.
26. Merali Z, Brennan K, Brau P and Anisman H: Dissociating anorexia and anhedonia elicited by interleukin-1beta: antidepressant and gender effects on responding for 'free chow' and 'earned' sucrose intake. Psychopharmacology (Berl) 165: 413-418, 2003.